Therapeutics News and Research

RSS

Palatin Technologies reports net loss of $2.0M for third-quarter 2010

Palatin Technologies, Inc., a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics, today announced results for its third quarter ended March 31, 2010.

13 May 2010

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

Atherotech Inc. will exhibit its VAP® Cholesterol Test in booth #102 at the National Lipid Association (NLA) Scientific Sessions 2010. The meeting takes place May 13-16 at the Sheraton Hotel and Towers in Chicago.

13 May 2010

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.

13 May 2010

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

BELLUS Health Inc. reported today its financial results for the first quarter ended March 31, 2010.

12 May 2010

Seaside purchases NanoViricides' Series B Convertible Preferred Stock for gross proceeds of $5M

NanoViricides, Inc., announced today that it has raised $5,000,000, drawing down on its previously announced universal registered shelf "Form S-3" offering. The registered shelf offering became effective on April 29, 2010.

12 May 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the first quarter, ended March 31, 2010.

12 May 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from the second of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.

12 May 2010

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of pre-clinical research in the journal Molecular Therapy revealing key mechanisms related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs).

12 May 2010

MicroStockProfit.com releases investment report featuring Hemispherx Biopharma

MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

12 May 2010

New approach to harness and modulate enzyme activity

An Arizona State University graduate student, Jinglin Fu, in collaboration with Biodesign Institute researchers Neal Woodbury and Stephen Albert Johnston, has pioneered a technique that improves on scientists' ability to harness and modulate enzyme activity.

12 May 2010

Evotec first-quarter operating loss decreases 93% to € 1.5 m

Evotec AG today reported financial results and corporate updates for the first quarter of 2010.

12 May 2010

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.

12 May 2010

Neurimmune Therapeutics honored with ZKB TECHNOPARK Pioneer Award

The ZKB TECHNOPARK® Pioneer Award, which has been sponsored by the Zürcher Kantonalbank since 2000, was presented for the 20th time at TECHNOPARK® Zurich. The award is given for technological innovations which - thanks to pioneering entrepreneurial achievements - are about to be launched on the market. This year's award winner is Neurimmune Therapeutics AG, represented by Dr. Jan Grimm, Professor Christoph Hock, Professor Roger Nitsch and Dr. Michael Salzmann.

12 May 2010

Oncos Therapeutics completes € 4 million investment from HealthCap

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

12 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

New combination therapy may help treat anti-estrogen resistant ER+ breast cancer

A study by researchers from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) identifies a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant in estrogen receptor positive breast cancers.

11 May 2010

Orexigen Therapeutics first-quarter net loss decreases to $14.1 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2010. For the quarter ended March 31, 2010, Orexigen reported a net loss of $14.1 million, or $0.30 per share attributable to common stockholders, as compared to a net loss of $19.3 million, or $0.56 per share attributable to common stockholders, for the first quarter of 2009.

11 May 2010

Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million

Alexza Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided a business update.

11 May 2010

ImmunoGen announces underwriter's exercise of over-allotment option

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase 1,350,000 shares of common stock at a public offering price of $8.00 per share.

10 May 2010